Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals
Background To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients. Methods Piecewise linear models were used to estimate CD4 count before and...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2018-06, Vol.66 (11), p.1785-1793 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1793 |
|---|---|
| container_issue | 11 |
| container_start_page | 1785 |
| container_title | Clinical infectious diseases |
| container_volume | 66 |
| creator | Unal, Guillemette Alessandri-Gradt, Elodie Leoz, Marie Pavie, Juliette Lefèvre, Clément Panjo, Henri Charpentier, Charlotte Descamps, Diane Barin, Francis Simon, François Meyer, Laurence Plantier, Jean-Christophe |
| description | Background To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients. Methods Piecewise linear models were used to estimate CD4 count before and after cART initiation. Kaplan-Meier survival curves were used to estimate time to reach clinical stage C before antiretroviral therapy (ART) and to analyze time to achieve a plasma viral load (pVL) |
| doi_str_mv | 10.1093/cid/cix1087 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04265280v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2085849239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-c7a3f455a6c55a1377cf374c7178b63b5fadc371f50460c501bd7d990b66fca33</originalsourceid><addsrcrecordid>eNpdkU1LAzEQhhdRsH6c_AMBL4qsJs1mk3grxdpCoSDVa0iziabsJmuyW-zdH25qiwcP88HMwzAzb5ZdIXiPIMcPylbJvhBk9CgbIIJpXhKOjlMOCcsLhtlpdhbjGkKEGCSD7HvaN9KBWdP0zlfaWGW1U1vwZkMfwXLbaoDAc_B9CxZg5oxWnfUOWAcmQTqlH8G4ts4qWYOJll0fdATSVYeBGxt87d9_2y86tt5FDToPRq6zQXdhB8g6XmQnJgV9eYjn2evkaTme5vPF82w8mucKl6TLFZXYFITIUiWHMKXKYFooiihblXhFjKwUpsgQWJRQEYhWFa04h6uyNEpifJ7d7ud-yFq0wTYybIWXVkxHc7GrwWJYkiGDG5TYmz3bBv_Z69iJxkal61o67fsoEKec0_RoktDrf-ja98GlS8QQMsIKPsQ8UXd7SgUfY9DmbwMExU49kdQTB_XwD81CjoY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2085849239</pqid></control><display><type>article</type><title>Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Unal, Guillemette ; Alessandri-Gradt, Elodie ; Leoz, Marie ; Pavie, Juliette ; Lefèvre, Clément ; Panjo, Henri ; Charpentier, Charlotte ; Descamps, Diane ; Barin, Francis ; Simon, François ; Meyer, Laurence ; Plantier, Jean-Christophe</creator><creatorcontrib>Unal, Guillemette ; Alessandri-Gradt, Elodie ; Leoz, Marie ; Pavie, Juliette ; Lefèvre, Clément ; Panjo, Henri ; Charpentier, Charlotte ; Descamps, Diane ; Barin, Francis ; Simon, François ; Meyer, Laurence ; Plantier, Jean-Christophe ; ORIVAO Study</creatorcontrib><description>Background To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients. Methods Piecewise linear models were used to estimate CD4 count before and after cART initiation. Kaplan-Meier survival curves were used to estimate time to reach clinical stage C before antiretroviral therapy (ART) and to analyze time to achieve a plasma viral load (pVL) <40 copies/mL following cART initiation. Immunovirological response was assessed at the most recent visit in patients on active follow-up. Results Data showed a 16.6% cumulative probability of reaching stage C within 5 years following diagnosis, and a mean CD4 decrease of –30.5 cells/μL/year. cART initiation in ART-naive patients led to a mean CD4 gain of 147 cells/μL after 12 months, and to a median pVL of <40 copies/mL after 3.8 months for 89.3%. Initiation with a nonrecommended nonnucleoside reverse transcriptase inhibitor–based vs a ritonavir-boosted protease inhibitor–based regimen resulted in a much smaller gain of around 100 CD4 cells/μL after 1 year. Patients on follow-up since 2007 had a median CD4 count of 498 cells/μL, and 87% had a pVL <40 copies/mL at the most recent follow-up visit. Conclusions This work provides unique data on HIV-1/O infection, in favor of a milder natural evolution than HIV-1 group M (HIV-1/M) and of a highly efficient current management, based on HIV-1/M guidelines, despite genetic divergence. Studies of comparable HIV-1/M and HIV-1/O populations are needed to confirm these results.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cix1087</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Antiviral agents ; CD4 antigen ; Divergence ; Drug therapy ; HIV ; Human immunodeficiency virus ; Humanities and Social Sciences ; Infections ; Life Sciences ; Non-nucleoside reverse transcriptase inhibitors ; Patients ; Protease inhibitors ; Proteinase inhibitors ; Ritonavir ; RNA-directed DNA polymerase ; Therapy ; Viruses</subject><ispartof>Clinical infectious diseases, 2018-06, Vol.66 (11), p.1785-1793</ispartof><rights>Copyright Oxford University Press Jun 1, 2018</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-c7a3f455a6c55a1377cf374c7178b63b5fadc371f50460c501bd7d990b66fca33</citedby><cites>FETCH-LOGICAL-c365t-c7a3f455a6c55a1377cf374c7178b63b5fadc371f50460c501bd7d990b66fca33</cites><orcidid>0000-0001-6417-4083 ; 0000-0003-1603-3635 ; 0000-0002-6150-2376 ; 0000-0003-3243-8018 ; 0000-0001-5707-2062 ; 0000-0002-8906-3416</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://hal.science/hal-04265280$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Unal, Guillemette</creatorcontrib><creatorcontrib>Alessandri-Gradt, Elodie</creatorcontrib><creatorcontrib>Leoz, Marie</creatorcontrib><creatorcontrib>Pavie, Juliette</creatorcontrib><creatorcontrib>Lefèvre, Clément</creatorcontrib><creatorcontrib>Panjo, Henri</creatorcontrib><creatorcontrib>Charpentier, Charlotte</creatorcontrib><creatorcontrib>Descamps, Diane</creatorcontrib><creatorcontrib>Barin, Francis</creatorcontrib><creatorcontrib>Simon, François</creatorcontrib><creatorcontrib>Meyer, Laurence</creatorcontrib><creatorcontrib>Plantier, Jean-Christophe</creatorcontrib><creatorcontrib>ORIVAO Study</creatorcontrib><title>Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals</title><title>Clinical infectious diseases</title><description>Background To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients. Methods Piecewise linear models were used to estimate CD4 count before and after cART initiation. Kaplan-Meier survival curves were used to estimate time to reach clinical stage C before antiretroviral therapy (ART) and to analyze time to achieve a plasma viral load (pVL) <40 copies/mL following cART initiation. Immunovirological response was assessed at the most recent visit in patients on active follow-up. Results Data showed a 16.6% cumulative probability of reaching stage C within 5 years following diagnosis, and a mean CD4 decrease of –30.5 cells/μL/year. cART initiation in ART-naive patients led to a mean CD4 gain of 147 cells/μL after 12 months, and to a median pVL of <40 copies/mL after 3.8 months for 89.3%. Initiation with a nonrecommended nonnucleoside reverse transcriptase inhibitor–based vs a ritonavir-boosted protease inhibitor–based regimen resulted in a much smaller gain of around 100 CD4 cells/μL after 1 year. Patients on follow-up since 2007 had a median CD4 count of 498 cells/μL, and 87% had a pVL <40 copies/mL at the most recent follow-up visit. Conclusions This work provides unique data on HIV-1/O infection, in favor of a milder natural evolution than HIV-1 group M (HIV-1/M) and of a highly efficient current management, based on HIV-1/M guidelines, despite genetic divergence. Studies of comparable HIV-1/M and HIV-1/O populations are needed to confirm these results.</description><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Antiviral agents</subject><subject>CD4 antigen</subject><subject>Divergence</subject><subject>Drug therapy</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humanities and Social Sciences</subject><subject>Infections</subject><subject>Life Sciences</subject><subject>Non-nucleoside reverse transcriptase inhibitors</subject><subject>Patients</subject><subject>Protease inhibitors</subject><subject>Proteinase inhibitors</subject><subject>Ritonavir</subject><subject>RNA-directed DNA polymerase</subject><subject>Therapy</subject><subject>Viruses</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkU1LAzEQhhdRsH6c_AMBL4qsJs1mk3grxdpCoSDVa0iziabsJmuyW-zdH25qiwcP88HMwzAzb5ZdIXiPIMcPylbJvhBk9CgbIIJpXhKOjlMOCcsLhtlpdhbjGkKEGCSD7HvaN9KBWdP0zlfaWGW1U1vwZkMfwXLbaoDAc_B9CxZg5oxWnfUOWAcmQTqlH8G4ts4qWYOJll0fdATSVYeBGxt87d9_2y86tt5FDToPRq6zQXdhB8g6XmQnJgV9eYjn2evkaTme5vPF82w8mucKl6TLFZXYFITIUiWHMKXKYFooiihblXhFjKwUpsgQWJRQEYhWFa04h6uyNEpifJ7d7ud-yFq0wTYybIWXVkxHc7GrwWJYkiGDG5TYmz3bBv_Z69iJxkal61o67fsoEKec0_RoktDrf-ja98GlS8QQMsIKPsQ8UXd7SgUfY9DmbwMExU49kdQTB_XwD81CjoY</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Unal, Guillemette</creator><creator>Alessandri-Gradt, Elodie</creator><creator>Leoz, Marie</creator><creator>Pavie, Juliette</creator><creator>Lefèvre, Clément</creator><creator>Panjo, Henri</creator><creator>Charpentier, Charlotte</creator><creator>Descamps, Diane</creator><creator>Barin, Francis</creator><creator>Simon, François</creator><creator>Meyer, Laurence</creator><creator>Plantier, Jean-Christophe</creator><general>Oxford University Press</general><general>Oxford University Press (OUP)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><scope>BXJBU</scope><orcidid>https://orcid.org/0000-0001-6417-4083</orcidid><orcidid>https://orcid.org/0000-0003-1603-3635</orcidid><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-3243-8018</orcidid><orcidid>https://orcid.org/0000-0001-5707-2062</orcidid><orcidid>https://orcid.org/0000-0002-8906-3416</orcidid></search><sort><creationdate>20180601</creationdate><title>Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals</title><author>Unal, Guillemette ; Alessandri-Gradt, Elodie ; Leoz, Marie ; Pavie, Juliette ; Lefèvre, Clément ; Panjo, Henri ; Charpentier, Charlotte ; Descamps, Diane ; Barin, Francis ; Simon, François ; Meyer, Laurence ; Plantier, Jean-Christophe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-c7a3f455a6c55a1377cf374c7178b63b5fadc371f50460c501bd7d990b66fca33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Antiviral agents</topic><topic>CD4 antigen</topic><topic>Divergence</topic><topic>Drug therapy</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humanities and Social Sciences</topic><topic>Infections</topic><topic>Life Sciences</topic><topic>Non-nucleoside reverse transcriptase inhibitors</topic><topic>Patients</topic><topic>Protease inhibitors</topic><topic>Proteinase inhibitors</topic><topic>Ritonavir</topic><topic>RNA-directed DNA polymerase</topic><topic>Therapy</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Unal, Guillemette</creatorcontrib><creatorcontrib>Alessandri-Gradt, Elodie</creatorcontrib><creatorcontrib>Leoz, Marie</creatorcontrib><creatorcontrib>Pavie, Juliette</creatorcontrib><creatorcontrib>Lefèvre, Clément</creatorcontrib><creatorcontrib>Panjo, Henri</creatorcontrib><creatorcontrib>Charpentier, Charlotte</creatorcontrib><creatorcontrib>Descamps, Diane</creatorcontrib><creatorcontrib>Barin, Francis</creatorcontrib><creatorcontrib>Simon, François</creatorcontrib><creatorcontrib>Meyer, Laurence</creatorcontrib><creatorcontrib>Plantier, Jean-Christophe</creatorcontrib><creatorcontrib>ORIVAO Study</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Unal, Guillemette</au><au>Alessandri-Gradt, Elodie</au><au>Leoz, Marie</au><au>Pavie, Juliette</au><au>Lefèvre, Clément</au><au>Panjo, Henri</au><au>Charpentier, Charlotte</au><au>Descamps, Diane</au><au>Barin, Francis</au><au>Simon, François</au><au>Meyer, Laurence</au><au>Plantier, Jean-Christophe</au><aucorp>ORIVAO Study</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals</atitle><jtitle>Clinical infectious diseases</jtitle><date>2018-06-01</date><risdate>2018</risdate><volume>66</volume><issue>11</issue><spage>1785</spage><epage>1793</epage><pages>1785-1793</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Background To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients. Methods Piecewise linear models were used to estimate CD4 count before and after cART initiation. Kaplan-Meier survival curves were used to estimate time to reach clinical stage C before antiretroviral therapy (ART) and to analyze time to achieve a plasma viral load (pVL) <40 copies/mL following cART initiation. Immunovirological response was assessed at the most recent visit in patients on active follow-up. Results Data showed a 16.6% cumulative probability of reaching stage C within 5 years following diagnosis, and a mean CD4 decrease of –30.5 cells/μL/year. cART initiation in ART-naive patients led to a mean CD4 gain of 147 cells/μL after 12 months, and to a median pVL of <40 copies/mL after 3.8 months for 89.3%. Initiation with a nonrecommended nonnucleoside reverse transcriptase inhibitor–based vs a ritonavir-boosted protease inhibitor–based regimen resulted in a much smaller gain of around 100 CD4 cells/μL after 1 year. Patients on follow-up since 2007 had a median CD4 count of 498 cells/μL, and 87% had a pVL <40 copies/mL at the most recent follow-up visit. Conclusions This work provides unique data on HIV-1/O infection, in favor of a milder natural evolution than HIV-1 group M (HIV-1/M) and of a highly efficient current management, based on HIV-1/M guidelines, despite genetic divergence. Studies of comparable HIV-1/M and HIV-1/O populations are needed to confirm these results.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1093/cid/cix1087</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6417-4083</orcidid><orcidid>https://orcid.org/0000-0003-1603-3635</orcidid><orcidid>https://orcid.org/0000-0002-6150-2376</orcidid><orcidid>https://orcid.org/0000-0003-3243-8018</orcidid><orcidid>https://orcid.org/0000-0001-5707-2062</orcidid><orcidid>https://orcid.org/0000-0002-8906-3416</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2018-06, Vol.66 (11), p.1785-1793 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04265280v1 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Antiviral agents CD4 antigen Divergence Drug therapy HIV Human immunodeficiency virus Humanities and Social Sciences Infections Life Sciences Non-nucleoside reverse transcriptase inhibitors Patients Protease inhibitors Proteinase inhibitors Ritonavir RNA-directed DNA polymerase Therapy Viruses |
| title | Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T00%3A51%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20Immunodeficiency%20Virus%20Type%201%20Group%20O%20Infection%20in%20France:%20Clinical%20Features%20and%20Immunovirological%20Response%20to%20Antiretrovirals&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Unal,%20Guillemette&rft.aucorp=ORIVAO%20Study&rft.date=2018-06-01&rft.volume=66&rft.issue=11&rft.spage=1785&rft.epage=1793&rft.pages=1785-1793&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/cix1087&rft_dat=%3Cproquest_hal_p%3E2085849239%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2085849239&rft_id=info:pmid/&rfr_iscdi=true |